P12.60.A PATIENT AGE IS RELATED TO FAVORABLE ASSOCIATION OF SUPRAMAXIMAL RESECTION WITH OUTCOME IN GLIOBLASTOMA - A REPORT OF THE RANO RESECT GROUP

Abstract BACKGROUND The oncological role of resection in elderly patients with glioblastoma remains controversial. We evaluated the value of resection in patients ≥65 years with (I) newly diagnosed and (II) recurrent glioblastoma by comparing the prognostic relevance of extent of resection to patients <65 years. MATERIAL AND METHODS The international RANO resect group retrospectively collected patients with newly diagnosed and recurrent IDH-wildtype glioblastoma from ten neuro-oncological centers. Associations of residual tumor with molecular and clinical markers on survival were analyzed. RESULTS 1260 patients with newly diagnosed glioblastoma were collected, including 512 elderly patients defined by an age of ≥65 years. While MGMT promotor methylation and subcortical tumor localization were both prognostic for favorable outcome and similar between age cohorts, KPS and second-line treatments differed between elderly and younger patients. Lower postoperative contrast-enhancing tumor volumes were favorably associated with survival on uni- and multivariate analyses; however, the effects on outcome were more pronounced in younger patients. Only in patients <65 years, supramaximal resection translated into more favorable survival (40 [CI: 22-56] vs. 20 [CI: 18-21] months, p=0.001). In 310 patients with first recurrence of a previously resected glioblastoma (including 92 patients ≥65 years), maximal resection of contrast-enhancing tumor was associated with favorable outcome particularly in younger patients (p=0.001) while neither elderly nor younger patients had definitive evidence for favorable effects of supramaximal resection. All findings were confirmed in propensity score-matched analyses to minimize confounding effects of inherent differences in demographic and clinical markers (including second-line treatments) between elderly and younger patients. CONCLUSION While complete contrast-enhancing tumor resection is prognostic for favorable outcome in patients ≥65 years, the associations of extensive (supramaximal) resection with improved outcomes are less pronounced compared to younger patients. Those findings highlight the relevance of tailored resection strategies in elderly patients, supporting individualized goals for extent of resection by acknowledging age.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-10-01
DOI
https://doi.org/10.1093/neuonc/noaf193.439
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P12.60.A PATIENT AGE IS RELATED TO FAVORABLE ASSOCIATION OF SUPRAMAXIMAL RESECTION WITH OUTCOME IN GLIOBLASTOMA - A REPORT OF THE RANO RESECT GROUP

J. C. Tonn, Jacob S. Young, Mitchel Stuart Berger, Christine Mau et al.
Neuro-Oncology
Glioma Diagnosis and Treatment
article

P12.60.A PATIENT AGE IS RELATED TO FAVORABLE ASSOCIATION OF SUPRAMAXIMAL RESECTION WITH OUTCOME IN GLIOBLASTOMA - A REPORT OF THE RANO RESECT GROUP

J. C. Tonn, Jacob S. Young, Mitchel Stuart Berger, Christine Mau, Levin Häni, Martin J. van den Bent, Stefan Josef Grau, Daniel P. Cahill, Michael Weller, Patrick Yung Wen, Gilbert Youssef, Annette M. Molinaro, Philipp Karschnia, Shawn L. Hervey‐Jumper, Oliver Schnell, Nitin Tandon, Jörg Dietrich, Nico Teske, Rong Huang, Francesco Bruno, Jürgen Beck, Antonio Dono, Maximilian I. Ruge, Tommaso Sciortino, Lorenzo Bello, Yoshua Esquenazi, Roberta Rudà, Stephanie T Juenger, Michael A. Vogelbaum, Susan M. Chang
article en

Abstract

Abstract BACKGROUND The oncological role of resection in elderly patients with glioblastoma remains controversial. We evaluated the value of resection in patients ≥65 years with (I) newly diagnosed and (II) recurrent glioblastoma by comparing the prognostic relevance of extent of resection to patients <65 years. MATERIAL AND METHODS The international RANO resect group retrospectively collected patients with newly diagnosed and recurrent IDH-wildtype glioblastoma from ten neuro-oncological centers. Associations of residual tumor with molecular and clinical markers on survival were analyzed. RESULTS 1260 patients with newly diagnosed glioblastoma were collected, including 512 elderly patients defined by an age of ≥65 years. While MGMT promotor methylation and subcortical tumor localization were both prognostic for favorable outcome and similar between age cohorts, KPS and second-line treatments differed between elderly and younger patients. Lower postoperative contrast-enhancing tumor volumes were favorably associated with survival on uni- and multivariate analyses; however, the effects on outcome were more pronounced in younger patients. Only in patients <65 years, supramaximal resection translated into more favorable survival (40 [CI: 22-56] vs. 20 [CI: 18-21] months, p=0.001). In 310 patients with first recurrence of a previously resected glioblastoma (including 92 patients ≥65 years), maximal resection of contrast-enhancing tumor was associated with favorable outcome particularly in younger patients (p=0.001) while neither elderly nor younger patients had definitive evidence for favorable effects of supramaximal resection. All findings were confirmed in propensity score-matched analyses to minimize confounding effects of inherent differences in demographic and clinical markers (including second-line treatments) between elderly and younger patients. CONCLUSION While complete contrast-enhancing tumor resection is prognostic for favorable outcome in patients ≥65 years, the associations of extensive (supramaximal) resection with improved outcomes are less pronounced compared to younger patients. Those findings highlight the relevance of tailored resection strategies in elderly patients, supporting individualized goals for extent of resection by acknowledging age.

Neuro-OncologyVol. 27(Supplement_3)
Brigham and Women's Hospital (US), Harvard University (US), University of Freiburg (DE), University of Cologne (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), University of Milan (IT), University of Zurich (CH), University Hospital of Bern (CH), University Medical Center Freiburg (DE), Moffitt Cancer Center (US), Massachusetts General Hospital (US), Universitätsklinikum Erlangen (DE), University Hospital of Zurich (CH), Neuroscience Institute (IT), Dana-Farber Cancer Institute (US), Center for Cancer Research (US), Erasmus MC Cancer Institute (NL), Klinikum Fulda (DE), The University of Texas Health Science Center (US), University of Turin (IT), University of San Francisco (US), Ludwig-Maximilians-Universität München (DE)
Openalex Percentile: Top 62%
Glioma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.